AstraZeneca Results Presentation Deck

Accelerating the expansion into immunology Good progress made with FTC¹ and other clearances AstraZeneca & 1. US Federal Trade Commission. 10 Compelling scientific complementarity and synergy Combination of two science- and patient-centric organisations Further-sustained, industry-leading double-digit revenue growth Improved profitability and strengthened cash flow ALEXION Alexion, the AstraZeneca rare disease unit B

View entire presentation